Latest Breaking News On - Siteman cancer center biostatistics shared - Page 1 : vimarsana.com

Giving chemotherapy in the morning rather than the evening could add a few months to patient survival, a new study shows. Glioblastoma is an aggressive type of brain cancer with no cure. Patients survive an average of 15 months after diagnosis, with fewer than 10% of patients surviving longer than five years. Average overall survival for all patients in the study, which appears in Neuro-Oncology Advances, was about 15 months after diagnosis. Those receiving the chemotherapy drug temozolomide in the morning had an average overall survival of about 17 months post diagnosis, compared with an average overall survival of about 13½ months for those taking the drug in the evening, a statistically significant difference of about 3½ months.

Annar damatoJoshuab rubinJianl campianErikd herzogSiteman cancer center biostatistics shared resourceBrain tumor center at sitemanSiteman cancer center at barnesLouis school of medicineWashington university school of medicineWashington university in stNeuro oncology advancesWashington universityLouis schoolSiteman cancer centerBarnes jewish hospitalWashington university school